Works in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2008, Vol 4, Issue 4
Results: 2478
P4-406: Tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, has no significant effect on drugs metabolized by CYP2C9
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-405: A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer's disease
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-404: Donepezil therapy for patients with Alzheimer's disease: Treatment benefits in “nonresponders”
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-403: Extended-release (ER) memantine capsule (28 mg, once daily): A multiple-dose, open-label study evaluating steady-state pharmacokinetics in healthy volunteers
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-402: Baseline cognitive and demographic characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-401: Identifying cognitive enhancement in man: Identifying efficacy in the dementias
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-400: A retrospective, observational study of cognitive, behavioral and functional outcomes in mild to moderate Alzheimer patients treated with cholinesterase inhibitors, or with gingko biloba or memantine
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-399: The somatotrophics, memory and aging research trial (SMART): Study of mental activity & resistance training for the prevention of cognitive impairment in at-risk older individuals
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-398: Identifying cognitive enhancement in man: Adding testing to routine phase I trials
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-397: Memantine treatment prevents clinical worsening: A pooled analysis of patients with moderate to severe Alzheimer's disease
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-396: Arizona Alzheimer's research registry part one: Rationale and design
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-395: Inhibition of CYP2C9 by fluconazole reduces clearance and increases exposure to tarenflurbil
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-394: Lack of evidence for the efficacy of memantine in mild Alzheimer's disease and modest effects in moderate Alzheimer's disease
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-393: Memory screening validation for Alzheimer prevention trials: The prevention of Alzheimer's disease by vitamin E and selenium (PREADVISE) study
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-392: The efficacy of souvenaid<sup>™</sup> in mild Alzheimer's disease: Design of a randomized, controlled, double-blind, parallel group, multicentre, multicountry clinical trial
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-391: A computerized cognitive assessment system as an alternative to the ADAS-cog in dementia trials
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-390: Identifying cognitive enhancement in man: Models and pharmacodynamic trials in volunteers
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-389: An oral antagonist of the receptor for advanced glycation end products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a phase II study
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-388: An exploratory study of the potential utility of plasma exchange with five percent human albumin Grifols<sup>®</sup> in the treatment of Alzheimer's disease: Functional imaging (SPECT) findings
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-387: Adding delayed recall to the Alzheimer's disease assessment scale–cognitive subscale (ADAS-cog): Sensitivity in a clinical trial for Alzheimer's disease and mild cognitive impairment
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-386: Exposure to tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, is not affected by administration with food
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-385: Development and validation of new measures of long-term memory consolidation
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-384: Tau Aggregation Inhibitor (TAI) therapy with rember<sup>™</sup> changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer's disease (AD)
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-383: Tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, has no significant effect on the pharmacokinetics and pharmacodynamics of warfarin
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-382: Effectiveness and safety of donepezil in Hispanic patients with mild to moderate Alzheimer's disease: A 12-week open-label study
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-381: Comparison of amisulpride and risperidone in the treatment of psychosis in patients with dementia of the Alzheimer's type
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-380: The challenges to the development of a safety biomarker assay to detect amyloid-β–specific T cell activation
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-379: Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple-dose administration of a gamma-secretase inhibitor in Japanese subjects
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-378: Intramuscular olanzapine versus intramuscular haloperidol for the treatment of delirium associated with Alzheimer's dementia: A randomized, open prospective study
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-377: Tarenflurbil a selective Aβ42-lowering agent, does not induce the metabolism of other drugs
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-376: A phase 3 multicenter trial of tarenflurbil in subjects with mild dementia of the Alzheimer's type (Act-Earli-AD): Rationale and methodology
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-375: Can insulin resistance in Alzheimer's disease be localized in the brain?
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-374: Curcumin reverses impaired insulin/IGF signaling and memory in streptozotocin induced memory deficit
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-373: Predictors of placebo group decline in the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) in 24-week clinical trials of Alzheimer's disease
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-372: Comparison of a slopes analysis using a mixed model to a traditional change from baseline analysis in an Alzheimer's disease clinical trial setting
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-364: Identifying cognitive enhancement in man: Showing benefits in conditions in which cognitive deficits are secondary
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-371: Arizona Alzheimer's research registry part two progress and findings from year one
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-368: The development of an immunological biomarker assay for use in a phase 1 Alzheimer's vaccine program
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-367: Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer's disease
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-366: GSI-953, a potent and selective gamma-secretase inhibitor: Modulation of beta-amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-365: Assessment of memantine treatment effects on language
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-369: Lithium trial in Alzheimer's disease: A randomized, single-blinded, placebo-controlled, parallel group multicentre 10-week study
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-363: A randomized clinical trial of vitamin E and memantine in Alzheimer's disease
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-362: Tarenflurbil clearance is not reduced in subjects with mild or moderate hepatic impairment
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-361: Assesment of the comparative effect of donepezil 10mg/d and placebo on radiological and biological markers in patients with amnestic mild cognitive impairment
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-360: Improved cognition in Alzheimer's disease with a partial nicotinic agonist as assessed with cogtest
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-359: Memory deficits in mild cognitive impairment are identified with cogtest
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-358: Acetylcholinesterase inhibitor dose-response effects on the neural correlates of semantic memory: Preliminary pharmacological fMRI data
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-357: Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch: Clinical data from two randomized trials
- Published in:
- 2008
- By:
- Publication type:
- Abstract
P4-356: Decreased activation along the dorsal visual pathway after three month treatment with galantamine in mild Alzheimer's disease: An fMRI study
- Published in:
- 2008
- By:
- Publication type:
- Abstract